Bridge Biotherapeutics
Korea - SeongnamBiotechnology
Focus: Bridge Biotherapeutics is a Korea-based small molecule biotech focused on immunology, respiratory, and oncology indications. The company operates at early-stage development with a pipeline spanning Phase 1 to Phase 2 programs.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About Bridge Biotherapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Bridge Biotherapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
10 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
BBT-401-1S
Ulcerative ColitisClinical Trials (1)
NCT04478825Efficacy and Safety of Rectally Administered BBT-401-1S in Subjects With Ulcerative Colitis
Phase 1Help build intelligence for Bridge Biotherapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.